Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients
| Autor: | Thomas Ibsen, Jan Lötvall, Mona Palmqvist, Anders Mellén |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Agonist medicine.drug_class Pharmacology Critical Care and Intensive Care Medicine Partial agonist Bronchial Provocation Tests Double-Blind Method immune system diseases Forced Expiratory Volume Formoterol Fumarate medicine Humans Albuterol Anti-Asthmatic Agents Salmeterol Xinafoate Asthma Cross-Over Studies Dose-Response Relationship Drug business.industry Airway Resistance Adrenergic beta-Agonists Middle Aged respiratory system medicine.disease Bronchodilator Agents respiratory tract diseases Ethanolamines Anesthesia Salbutamol Female Bronchoconstriction Methacholine Salmeterol Formoterol medicine.symptom business hormones hormone substitutes and hormone antagonists circulatory and respiratory physiology medicine.drug |
| Zdroj: | American Journal of Respiratory and Critical Care Medicine. 160:244-249 |
| ISSN: | 1535-4970 1073-449X |
| DOI: | 10.1164/ajrccm.160.1.9901063 |
| Popis: | Studies performed on airway smooth muscle in vitro have indicated that salmeterol is a partial agonist on the b 2 -receptor in comparison to formoterol. In the present study we evaluated whether these pharmacological differences between salmeterol and formoterol also are applicable to asthmatic patients. The protective effects by increasing cumulative doses of formoterol (12, 60, 120 m g) and salmeterol (50, 250, 500 m g) on methacholine-induced bronchoconstriction were evaluated in a double-blind, crossover, placebo-controlled design. Patients were regularly treated with salbutamol 200 m g twice daily during the study period, to avoid variability in b 2 -adrenoceptor tolerance. S-potassium, heart rate corrected Q-T interval (Q-T c ), and tremor score were followed as measures of systemic effects. Formoterol dose-dependently protected against methacholine responsiveness (4.6 doubling doses after 120 m g). Salmeterol, however, showed a flatter dose‐response curve, and a significantly weaker maximal protective effect (2.8 doubling doses after 250 m g). Formoterol caused a significantly higher tremor score and a larger drop in S-potassium than salmeterol at the highest doses. These data show that salmeterol is a partial agonist on the b 2 -receptor in relation to formoterol in human airways in vivo. Further studies are required to document the clinical consequences of this finding, for example in severe asthmatic patients. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. AM J RESPIR CRIT CARE MED 1999;160:244‐249. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|